Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessio Ciulli

Showing results (41-50 of 163) with videos related to

Pageof 17
Sort By:
Protein Expression and Purification|March 5, 2026
Scalable insect cell expression and purification screening applied to CRL4-DCAF substrate receptorsAngus D Cowan, Stefan Jaekel, Alessio Ciulli
Methods in Molecular Biology (Clifton, N.J.)|August 25, 2021
Mechanistic and Structural Features of PROTAC Ternary ComplexesRyan Casement, Adam Bond, Conner Craigon, et al.
Journal of Bacteriology|July 21, 2005
Salicylate biosynthesis: overexpression, purification, and characterization of Irp9, a bifunctional salicylate synthase from Yersinia enterocoliticaOlivier Kerbarh, Alessio Ciulli, Nigel I Howard, et al.
Journal of Medicinal Chemistry|June 9, 2017
Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor ScaffoldsKwok-Ho Chan, Michael Zengerle, Andrea Testa, et al.
Structure (London, England : 1993)|June 8, 2017
Crystal Structure of the Cul2-Rbx1-EloBC-VHL Ubiquitin Ligase ComplexTeresa A F Cardote, Morgan S Gadd, Alessio Ciulli
Expert Opinion on Therapeutic Patents|January 21, 2025
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019-present)Aina Urbina, Alex J Hallatt, Jack Robertson, et al.
Current Opinion in Pharmacology|April 2, 2021
Transforming targeted cancer therapy with PROTACs: A forward-looking perspectiveWilliam Farnaby, Manfred Koegl, Darryl B McConnell, et al.
Frontiers in Immunology|December 16, 2024
Unravelling the druggability and immunological roles of the SOCS-family proteinsDylan M Lynch, Beth Forrester, Thomas Webb, et al.
Methods in Molecular Biology (Clifton, N.J.)|August 25, 2021
MST and TRIC Technology to Reliably Study PROTAC Binary and Ternary Binding in Drug DevelopmentTanja Bartoschik, Andreas Zoephel, Klaus Rumpel, et al.
Nature Reviews. Cancer|April 25, 2025
Targeted protein degradation for cancer therapyMatthias Hinterndorfer, Valentina A Spiteri, Alessio Ciulli, et al.
Pageof 17

Showing results (41-50 of 163) with videos related to

Sort By:
Pageof 17
Protein Expression and Purification|March 5, 2026
Scalable insect cell expression and purification screening applied to CRL4-DCAF substrate receptorsAngus D Cowan, Stefan Jaekel, Alessio Ciulli
Methods in Molecular Biology (Clifton, N.J.)|August 25, 2021
Mechanistic and Structural Features of PROTAC Ternary ComplexesRyan Casement, Adam Bond, Conner Craigon, et al.
Journal of Bacteriology|July 21, 2005
Salicylate biosynthesis: overexpression, purification, and characterization of Irp9, a bifunctional salicylate synthase from Yersinia enterocoliticaOlivier Kerbarh, Alessio Ciulli, Nigel I Howard, et al.
Journal of Medicinal Chemistry|June 9, 2017
Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor ScaffoldsKwok-Ho Chan, Michael Zengerle, Andrea Testa, et al.
Structure (London, England : 1993)|June 8, 2017
Crystal Structure of the Cul2-Rbx1-EloBC-VHL Ubiquitin Ligase ComplexTeresa A F Cardote, Morgan S Gadd, Alessio Ciulli
Expert Opinion on Therapeutic Patents|January 21, 2025
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019-present)Aina Urbina, Alex J Hallatt, Jack Robertson, et al.
Current Opinion in Pharmacology|April 2, 2021
Transforming targeted cancer therapy with PROTACs: A forward-looking perspectiveWilliam Farnaby, Manfred Koegl, Darryl B McConnell, et al.
Frontiers in Immunology|December 16, 2024
Unravelling the druggability and immunological roles of the SOCS-family proteinsDylan M Lynch, Beth Forrester, Thomas Webb, et al.
Methods in Molecular Biology (Clifton, N.J.)|August 25, 2021
MST and TRIC Technology to Reliably Study PROTAC Binary and Ternary Binding in Drug DevelopmentTanja Bartoschik, Andreas Zoephel, Klaus Rumpel, et al.
Nature Reviews. Cancer|April 25, 2025
Targeted protein degradation for cancer therapyMatthias Hinterndorfer, Valentina A Spiteri, Alessio Ciulli, et al.
Pageof 17